Institutional Repository of Vilnius University
Ortokeratologiniai lęšiai ir trumparegystės progresavimas. Literatūros apžvalga /
Abstract
dc:descriptionMyopia is one of the fastest-growing visual disorders worldwide, projected to affect approximately 50% of the global population by 2050. High myopia is of particular concern due to its increased risk of retinal detachment, glaucoma, and maculopathy complications, making timely and effective slowing of myopia progression an important goal in clinical ophthalmology and optometry. Orthokeratology is a non-surgical vision correction method in which rigid gas-permeable contact lenses with a reverse geometry design, worn overnight, temporarily reshape the cornea, providing clear daytime vision without the need for additional optical aids. A systematic review of scientific literature published from 2020 to 2026 examined orthokeratology lens design principles, corneal reshaping mechanisms, and pathways for myopia control. Peripheral myopic defocus resulting from corneal shape changes was identified as the primary mechanism of myopia control, while hydraulic force-driven corneal epithelial redistribution was established as the principal morphological mechanism. Choroidal thickness changes were identified as a promising biomarker of treatment efficacy. Analysis of major clinical trials and meta-analyses showed that orthokeratology reduces axial elongation by approximately 30-60% over two years compared with other optical corrections. Treatment efficacy is influenced by age, baseline refraction, back optic zone diameter, pupil size, treatment zone decentration, environmental factors, and genetic predisposition. Safety analysis indicated a microbial keratitis risk of approximately 4.9-5.3 cases per 10,000 patient-years in contemporary studies - comparable to that of daily soft contact lens wear. A comparative evaluation of orthokeratology, low-dose atropine, multifocal soft contact lenses (MiSight), and specialised spectacle lenses (DIMS, HALT) is provided, along with an assessment of the additive benefit of combination therapy with 0.01–0.05% atropine in children with rapid myopia progression.
Degree
thesis:*- Grantor dc:publisher
- Institutional Repository of Vilnius University
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Šimkutė, Paulina,
Rights
dc:rights- Statement dc:rights
-
- info:eu-repo/semantics/openAccess
- Language dc:language
- lit
Identifiers
dc:identifier.*- Repository record dc:identifier
- https://repository.vu.lt/VU:ELABAETD308321652&prefLang=en_US